Allied delivers a variety of psilocybin and cannabis formulations for health and wellness applications. Depression, Anxiety and PTSD are Allied’s priority. With extensive expertise in medical discovery and research, cannabis & psilocybin cultivation and processing, proprietary products and natural health product distribution, we are fully integrated across the value chain.

Expected Milestones


  • Production 1-10 Hectares in Colombia & US foot print
  • Psilocybin company acquisition 
  • Distribution of Natural Health products 
  • Pharma clinincal trials

Investor Info
Allied Slide Deck

Expected Milestones


  • Cultivation scaled (cannabis and psilocybin)
  • Pharma products brought through clinical trials 
  • Natural health products sales & distribution scaled

Allied Corp. is dedicated to helping people. As a research and development company, our focus is on creating and providing targeted psilocybin & cannabinoid health solutions for today’s medical issues. One of our top R&D priorities is developing products for General Depression, Anxiety and PTSD.

Why Allied?

We are unique in our ‘full scope’ approach to psilocybin and cannabis approach. The global cannabis and psilocybin market is expected to grow from $11bn to $56bn by 2025. South America is positioned to become the new global supply source as global demand will outstrip supply. Allied is ready.

We also have a purposeful strategy to be in line for US legalization. While we grow each of Allied’s business segment to realize revenue, Allied will continue to expand upon emerging scientific discoveries in new markets such as the psilocybin space.

Low Cost, High Quality, High Margin

Low cost of production – $0.09-0.15 per gram of dry flower vs average of $1.52/ gram in Canada. Low-cost, high-margin model.

Ability To Scale

One thing that our production site is not is land constrained. We have the ability to custom produce a cannabinoid profile to customer specifications and international pharmacopeia standards.

Advanced Research & Technology

Our proprietary production approach provides a pharma approach to formulation and medical discovery. Along with pre-clinical research from Israel, we plan to have several Pharma and Natural Health products to market to serve general mental health disease targets.

Experienced Management Team

Decades of production and extraction expertise. Strong regional and agricultural specialists in each country. Experienced business support team active in market support and production execution.

Our Story

Our mission is to help people around the world by creating and providing targeted psilocybin and cannabinoid health solutions using pharmaceutical R&D, innovative plant-based production, and unique development of therapeutic products.



Our operations span from a large production center in South America to R&D of targeted psilocybin and cannabinoid health solutions in Canada for today’s medical issues. Our end-to-end business model enables Allied to bring unique products to market.


Investor Information

Allied Charitable Activities

Our charitable based activities support many organizations around the globe. In-person healing retreats, supportive athletic events and connection to a peer-community provide on-going support for veterans, police, fire, and emergency health first-responders.


Sign up to our newsletter and receive latest investor news, events, and other important information related to Allied Health.

Keep Informed